Reimbursement framework for medical devices in India

India is an emerging medical device market with huge potential due to its vast population, increasing income, rising healthcare demand, along with increased health insurance coverage. Government-backed schemes such as Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY) have significantly extended the reach of healthcare services (including medical devices) to wider population. Also, the newly instituted Health Financing and Technology Assessment (HeFTA) unit within the National Health Authority (NHA) will have a greater positive impact on the reimbursement framework in the coming years.

The growth and sustainability of any market, and making innovative technologies accessible to patients depends on a solid reimbursement framework and open price considerations. Considering India’s remarkable growth potential in the medical devices sector, certain aspects of the current reimbursement and pricing framework must be re-evaluated to enable continuing market expansion and access to trailblazing healthcare innovations for patients.

Open PDF

Return to Insights Center

Related Insights


Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress

May 2, 2024


Addressing the Challenges of Artificial Intelligence used for Data Extraction in Systematic Literature Reviews

Mar 15, 2023


Three strategies for articulating a coherent product value story

Dec 18, 2021


Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs

Feb 8, 2022


How biotechs can strengthen their value story with advanced analytics

Feb 15, 2022


Overview of China's Market Approval Policy Med Insurance Payment System

Apr 7, 2022


China's Market Approval Policy and Medical Insurance Payment System for Rare Disease

Jul 21, 2022


Preparing for a new era in European Market Access

Jul 22, 2022


U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?

Aug 17, 2022


Why Rare Disease Therapeutics Need Early Market Access Planning

Jan 4, 2023


Innovative modeling method could speed patient access to critical IO therapies

Jan 4, 2023


Are you using real-world evidence?

Feb 1, 2023